Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04876456 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
A Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, sponsored by Jennifer King.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04876456: Active Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, sponsored by Jennifer King.
NCT04876456 is a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor that is active but no longer recruiting, run by Jennifer King. The registered enrollment target is 50 participants, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04876456, a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, is active but no longer recruiting, sponsored by Jennifer King.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.
Primary Outcome
determined by the proportion of complete responses, partial responses, and stable disease for at least 3 months of therapy using RECIST 1.1 while including markers AFP/ beta-hcg.
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What the registry record for NCT04876456 still lists
NCT04876456 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT04876456 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04876456 about?
NCT04876456 is a clinical study titled "A Phase II Trial of Cabozantinib With Patients With Refractory GCTs". The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for w...
What is the current status of trial NCT04876456?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-06-10. Estimated completion is 2027-01.
What conditions does trial NCT04876456 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Ovarian Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Seminoma.
What interventions are being tested in trial NCT04876456?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04876456?
This trial is sponsored by Jennifer King, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04876456 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04876456's enrollment target sits among peer trials
50 11th of 19 higher than 9 of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
RECRUITING · Phase 2
-
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI